[go: up one dir, main page]

CL2020002012A1 - Formulaciones de anticuerpos humanos anti-rankl y métodos de uso de estas. (divisional solicitud 201903032) - Google Patents

Formulaciones de anticuerpos humanos anti-rankl y métodos de uso de estas. (divisional solicitud 201903032)

Info

Publication number
CL2020002012A1
CL2020002012A1 CL2020002012A CL2020002012A CL2020002012A1 CL 2020002012 A1 CL2020002012 A1 CL 2020002012A1 CL 2020002012 A CL2020002012 A CL 2020002012A CL 2020002012 A CL2020002012 A CL 2020002012A CL 2020002012 A1 CL2020002012 A1 CL 2020002012A1
Authority
CL
Chile
Prior art keywords
methods
human anti
antibody formulations
rankl antibody
divisional request
Prior art date
Application number
CL2020002012A
Other languages
English (en)
Inventor
Lyanne M Wong
Jaymille Fallon
Monica Michelle Goss
Jian Hua Gu
Pavan K Ghattyvenkatakrishna
Stephen Robert Brych
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62165668&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2020002012(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CL2020002012A1 publication Critical patent/CL2020002012A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

En la presente se describen formulaciones farmacéuticas acuosas que comprenden el anticuerpo monoclonal anti-RANKL humano o parte de este, y características de pH, sistemas tampón e inhibidores de agregación de aminoácidos. También se describen métodos de uso de las formulaciones para prevenir o tratar enfermedades.
CL2020002012A 2017-04-28 2020-07-31 Formulaciones de anticuerpos humanos anti-rankl y métodos de uso de estas. (divisional solicitud 201903032) CL2020002012A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762492056P 2017-04-28 2017-04-28

Publications (1)

Publication Number Publication Date
CL2020002012A1 true CL2020002012A1 (es) 2020-10-16

Family

ID=62165668

Family Applications (3)

Application Number Title Priority Date Filing Date
CL2019003032A CL2019003032A1 (es) 2017-04-28 2019-10-23 Formulaciones de anticuerpos humanos anti-rankl y métodos de uso de estas.
CL2020002012A CL2020002012A1 (es) 2017-04-28 2020-07-31 Formulaciones de anticuerpos humanos anti-rankl y métodos de uso de estas. (divisional solicitud 201903032)
CL2023002505A CL2023002505A1 (es) 2017-04-28 2023-08-24 Formulaciones de anticuerpos humanos anti-rankl y métodos de uso de estas

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2019003032A CL2019003032A1 (es) 2017-04-28 2019-10-23 Formulaciones de anticuerpos humanos anti-rankl y métodos de uso de estas.

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2023002505A CL2023002505A1 (es) 2017-04-28 2023-08-24 Formulaciones de anticuerpos humanos anti-rankl y métodos de uso de estas

Country Status (37)

Country Link
US (3) US11192952B2 (es)
EP (3) EP4190355B1 (es)
JP (4) JP7190822B2 (es)
KR (2) KR20240110083A (es)
CN (2) CN110621342B (es)
AR (1) AR111497A1 (es)
AU (2) AU2018260750B2 (es)
BR (1) BR112019022188A2 (es)
CA (1) CA3054165A1 (es)
CL (3) CL2019003032A1 (es)
CO (1) CO2019011463A2 (es)
CR (2) CR20250034A (es)
DK (2) DK3615066T5 (es)
EA (1) EA201992570A1 (es)
ES (2) ES2973572T3 (es)
FI (2) FI3615066T3 (es)
HR (2) HRP20240167T1 (es)
HU (2) HUE065544T2 (es)
IL (2) IL293127B2 (es)
JO (1) JOP20190255A1 (es)
LT (2) LT3615066T (es)
MA (2) MA48462B1 (es)
MX (1) MX2023013460A (es)
MY (1) MY202479A (es)
PE (2) PE20251534A1 (es)
PH (1) PH12019502444A1 (es)
PL (2) PL4190355T3 (es)
PT (2) PT4190355T (es)
RS (2) RS65299B1 (es)
SG (1) SG11201909998TA (es)
SI (2) SI4190355T1 (es)
SM (2) SMT202400095T1 (es)
TN (2) TN2019000297A1 (es)
TW (1) TWI839331B (es)
UY (2) UY37707A (es)
WO (1) WO2018200918A1 (es)
ZA (1) ZA202205141B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190255A1 (ar) 2017-04-28 2019-10-27 Amgen Inc صيغ أجسام مضادة لـ rankl بشري، وطرق لاستخدامها
MA48461A (fr) * 2017-04-28 2020-03-04 Amgen Inc Excipients pour réduire la viscosité de formulations d'anticorps et compositions de formulation
EP3881865A4 (en) * 2018-11-16 2022-07-20 Samsung Bioepis Co., Ltd. STABLE LIQUID COMPOSITION WITH PROTEIN
CN109374779A (zh) * 2018-12-17 2019-02-22 杭州奕安济世生物药业有限公司 一种蔗糖含量的快速检测方法
CR20210435A (es) 2019-02-18 2021-09-20 Lilly Co Eli Formulación de anticuerpos terapéuticos
AU2020347729C1 (en) * 2019-09-19 2025-12-18 Innovent Biologics (Suzhou) Co., Ltd. Method for preventing or treating cholesterol-related diseases by using anti-PCSK9 antibody
CN111704670B (zh) * 2020-08-18 2020-11-03 迈威(上海)生物科技股份有限公司 重组抗RANKL抗体IgG2型的二硫键异构体及其纯化方法
WO2022103660A1 (en) * 2020-11-11 2022-05-19 Hq Han Bifunctional antagonists of activin/tgf-beta and rankl and uses thereof
MX2023013165A (es) * 2021-05-12 2023-11-30 Jiangsu Hengrui Pharmaceuticals Co Ltd Molecula de union a antigeno que se une especificamente a rankl y ngf, y su uso medico.
KR20240046881A (ko) 2021-08-12 2024-04-11 암젠 인크 항체 제형
WO2023092177A1 (en) * 2021-11-23 2023-06-01 Adalta Limited Rank-l binding molecules
CN118139882A (zh) * 2022-03-24 2024-06-04 安济盛生物医药有限公司 骨骼肌肉系统疾病的治疗
WO2024064878A1 (en) 2022-09-23 2024-03-28 The University Of North Carolina At Chapel Hill Methods and compositions for the treatment of melanoma
WO2024104409A1 (zh) * 2022-11-16 2024-05-23 苏州盛迪亚生物医药有限公司 一种含抗rankl-ngf双特异性抗体的药物组合物
EP4676959A1 (en) 2023-03-03 2026-01-14 Alvotech HF Denosumab formulation
WO2025036493A1 (en) * 2023-08-17 2025-02-20 Sinomab Bioscience Limited Antibodies targeting rankl and sclerostin and uses thereof
WO2025116648A1 (ko) * 2023-12-01 2025-06-05 삼성바이오에피스 주식회사 항-IL-4Rα 항체의 안정한 완충제-프리 액상 제형

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12012502439A1 (en) 2001-06-26 2013-06-17 Amgen Inc Antibodies to opgl
PE20070684A1 (es) 2005-11-14 2007-08-06 Amgen Inc MOLECULAS QUIMERICAS DE ANTICUERPO RANKL-PTH/PTHrP
US20080213282A1 (en) * 2006-12-21 2008-09-04 Jaby Jacob Formulations
CA2692165A1 (en) 2007-06-25 2008-12-31 Amgen Inc. Compositions of specific binding agents to hepatocyte growth factor
WO2009099641A2 (en) * 2008-02-07 2009-08-13 Amgen Inc. Stabilized protein compositions
CL2009001735A1 (es) 2008-08-19 2010-02-19 Regeneron Pharma Anticuerpo humano o fragmento de union a antigeno del mismo que une e inhibe actividad de ligando del activador del receptor de nf-kb (rankl); adn codificante; vector de expresion; metodo para producir dicho anticuerpo; composicion farmaceutica que lo comprende; uso para atenuar o inhibir enfermedad o condicion mediada por rankl
EP2684570A1 (en) 2008-09-10 2014-01-15 F. Hoffmann-La Roche AG Compositions and methods for the prevention of oxidative degradation of proteins
US9265834B2 (en) * 2009-03-05 2016-02-23 Ablynx N.V. Stable formulations of polypeptides and uses thereof
TWI440470B (zh) 2009-03-19 2014-06-11 Chugai Pharmaceutical Co Ltd 含改良抗體分子之醫藥配方
EP2568960B1 (en) 2010-05-10 2018-06-06 Intas Pharmaceuticals Ltd. Liquid formulation of polypeptides containing an fc domain of an immunoglobulin
EP2433644A1 (en) 2010-09-22 2012-03-28 IMBA-Institut für Molekulare Biotechnologie GmbH Breast cancer therapeutics
WO2012141978A2 (en) * 2011-04-07 2012-10-18 Glaxosmithkline Llc Formulations with reduced viscosity
WO2013012022A1 (ja) 2011-07-19 2013-01-24 中外製薬株式会社 アルギニンアミドまたはその類似化合物を含む安定なタンパク質含有製剤
WO2013063510A1 (en) 2011-10-28 2013-05-02 Integritybio Inc. Protein formulations containing amino acids
TWI679019B (zh) 2013-04-29 2019-12-11 法商賽諾菲公司 抗ｉｌ－４／抗ｉｌ－１３之雙特異性抗體調配物
CN103965357B (zh) 2013-12-31 2016-08-17 嘉和生物药业有限公司 一种抗人rankl抗体
WO2015121318A1 (en) 2014-02-12 2015-08-20 Sanofi Anti-il-4/anti-il-13 bispecific antibody/polyglutamate formulations
WO2015134406A1 (en) * 2014-03-03 2015-09-11 La Jolla Biologics, Inc. Stable aqueous recombinant protein formulations
KR102385802B1 (ko) 2014-05-07 2022-04-13 다케다 야쿠힝 고교 가부시키가이샤 Gm-csf 중화 화합물을 포함하는 액체 제제
JP2018500380A (ja) 2014-12-31 2018-01-11 ノベルメド セラピューティクス，インコーポレーテッド アグリコシル化治療用抗体の製剤
WO2016162819A1 (en) 2015-04-07 2016-10-13 Lupin Limited Stable aqueous pharmaceutical composition of anti-tnf alpha antibody
JOP20190255A1 (ar) 2017-04-28 2019-10-27 Amgen Inc صيغ أجسام مضادة لـ rankl بشري، وطرق لاستخدامها

Also Published As

Publication number Publication date
ES2997833T3 (en) 2025-02-18
CR20250034A (es) 2025-03-06
CL2019003032A1 (es) 2020-02-21
US20200354463A1 (en) 2020-11-12
CN110621342A (zh) 2019-12-27
JOP20190255A1 (ar) 2019-10-27
TW201841654A (zh) 2018-12-01
DK3615066T3 (da) 2024-03-11
PT3615066T (pt) 2024-03-08
ZA202205141B (en) 2025-04-30
PL3615066T3 (pl) 2024-04-29
EP4190355B1 (en) 2024-09-25
HUE065544T2 (hu) 2024-05-28
CN110621342B (zh) 2024-08-02
LT3615066T (lt) 2024-02-26
PE20200343A1 (es) 2020-02-14
JP7190822B2 (ja) 2022-12-16
FI4190355T3 (fi) 2024-12-07
KR20240110083A (ko) 2024-07-12
AR111497A1 (es) 2019-07-17
WO2018200918A1 (en) 2018-11-01
HRP20241604T1 (hr) 2025-01-31
SG11201909998TA (en) 2019-11-28
DK4190355T3 (da) 2024-12-09
PT4190355T (pt) 2024-12-05
MA48462B1 (fr) 2024-05-31
JP7356525B2 (ja) 2023-10-04
SMT202400491T1 (it) 2025-01-14
JP2023166396A (ja) 2023-11-21
HUE069382T2 (hu) 2025-03-28
AU2025205470A1 (en) 2025-08-14
CN118987200A (zh) 2024-11-22
MX2023013460A (es) 2023-12-15
IL293127A (en) 2022-07-01
JP2018188430A (ja) 2018-11-29
EP3615066B1 (en) 2023-12-27
UY37707A (es) 2018-10-31
US20250326853A1 (en) 2025-10-23
PE20251534A1 (es) 2025-06-05
SI4190355T1 (sl) 2025-02-28
IL293127B2 (en) 2024-06-01
CL2023002505A1 (es) 2024-03-08
BR112019022188A2 (pt) 2020-05-12
MA48462A (fr) 2020-03-04
IL268704A (en) 2019-10-31
FI3615066T3 (fi) 2024-02-29
JP2022062059A (ja) 2022-04-19
US11192952B2 (en) 2021-12-07
AU2018260750B2 (en) 2025-04-17
DK3615066T5 (da) 2024-09-02
MA62173B1 (fr) 2025-01-31
US11873343B2 (en) 2024-01-16
RS66284B1 (sr) 2025-01-31
PL4190355T3 (pl) 2025-02-10
RS65299B1 (sr) 2024-04-30
KR20190140464A (ko) 2019-12-19
CR20190538A (es) 2020-02-26
IL268704B (en) 2022-06-01
KR102681171B1 (ko) 2024-07-05
SI3615066T1 (sl) 2024-04-30
EP4477667A3 (en) 2025-05-07
TW202435914A (zh) 2024-09-16
CO2019011463A2 (es) 2019-10-31
EA201992570A1 (ru) 2020-03-20
TN2019000297A1 (en) 2021-05-07
EP4477667A2 (en) 2024-12-18
LT4190355T (lt) 2024-12-27
EP3615066A1 (en) 2020-03-04
IL293127B1 (en) 2024-02-01
MY202479A (en) 2024-04-30
SMT202400095T1 (it) 2024-05-14
TWI839331B (zh) 2024-04-21
TN2021000055A1 (en) 2022-10-03
CA3054165A1 (en) 2018-11-01
PH12019502444A1 (en) 2020-07-20
JP2025093923A (ja) 2025-06-24
ES2973572T3 (es) 2024-06-20
US20220143181A1 (en) 2022-05-12
UY40974A (es) 2024-12-13
EP4190355A1 (en) 2023-06-07
WO2018200918A8 (en) 2019-10-17
AU2018260750A1 (en) 2019-08-29
HRP20240167T1 (hr) 2024-04-26

Similar Documents

Publication Publication Date Title
CL2020002012A1 (es) Formulaciones de anticuerpos humanos anti-rankl y métodos de uso de estas. (divisional solicitud 201903032)
CL2020001974A1 (es) Anticuerpos anti-trem2 y métodos para utilizarlos. (divisional solicitud 201903093)
CL2019002478A1 (es) Formulación de anticuerpo monoclonal anti-vrs.
CO2019011021A2 (es) Formulacion estable de anticuerpos
MX2020008219A (es) Formulacion farmaceutica de ph bajo.
BR112015022210A2 (pt) formulações farmacêuticas aquosas estáveis, seu uso, artigo de manufatura, métodos de redução da agregação de um anticorpo monoclonal terapêutico e método de produção de uma formulação farmacêutica.
NZ719036A (en) Anti-pdl1 antibody formulations
MX2015015152A (es) Formulaciones de anticuerpos biespecificos anti-il-4/anti-il-13.
PE20181092A1 (es) Anticuerpos anti-pd1 y metodos de uso
JOP20190189A1 (ar) تركيبة صيدلانية ذات درجة حموضة منخفضة تتضمن بنيات جسم مضاد يستهدف الخلية t
CL2018000226A1 (es) Mezcla de péptidos (divisional solicitud 201601405)
BR112017004393A2 (pt) formulações de anticorpo
CO2021010697A2 (es) Formulación de anticuerpos terapéuticos
CO2020016008A2 (es) Formulación de proteína de fusión estable
EA202091563A1 (ru) Человеческие антитела к гемагглютинину вируса гриппа
AR117607A1 (es) Formulaciones de anticuerpo líquidas de alta concentración
CO2020013545A2 (es) Formulación estable de anticuerpos
BR112018011590A2 (pt) formulação cosmética
AR109252A1 (es) Formulaciones de anticuerpos